

A Longitudinally-Aware Segmentation Network for Automatic Interim PET Analysis in Pediatric Hodgkin Lymphoma Patients

SNMMI 2024
June 10, 2024

Xin Tie, Muheon Shin, Changhee Lee, Scott B. Perlman, Zachary Huemann, Sharon M. Castellino, Kara M. Kelly, Junjie Hu, Steve Y. Cho, Tyler J. Bradshaw

Department of Radiology
University of Wisconsin



University of Wisconsin
**SCHOOL OF MEDICINE
AND PUBLIC HEALTH**





Disclosures



No disclosures


Quantitative PET biomarkers in guiding lymphoma treatment strategies



1. Cottreau AS, et al. *J Nucl Med.* 2020; 61(1):40-45.
2. Rossi C, et al. *J Nucl Med.* 2014; 55(4):569-573.


■ Deep learning (DL) for automatic PET analysis

- Segment lymphoma
- Quantify **baseline** tumor burden



Baseline PET

TMTV	878.6 ml
TLG	3664 g
SUVmax	17.8 g/ml
...	...



Baseline PET

TMTV	499.0 ml
TLG	3061 g
SUVmax	10.8 g/ml
...	...

■ Interim PET analysis

- Response assessments
- Guide treatment
- ***Few attempts !***

— Initial lymphoma

— Residual lymphoma



Baseline PET



Interim PET


Deauville scores

— Initial lymphoma

— Residual lymphoma



Baseline PET



Interim PET

Deauville score: 4

Deauville scores


Quantitative biomarkers

— Initial lymphoma

— Residual lymphoma



Baseline PET



Interim PET

ΔSUV_{max} : 63.6%

$qPET$: 2.19

Challenges of Interim PET analysis


- Subtle tumor uptake
- Difficult to differentiate from inflammatory activity

— Initial lymphoma

— Residual lymphoma



Baseline PET



Interim PET




Baseline PET



Interim PET

Physicians rely on **cross comparison** with baseline PET

- Methods for incorporating prior images are underexplored




Purpose




To develop a novel longitudinally-aware segmentation network that can detect residual disease on interim PET scans utilizing baseline PET data

- Two Children's Oncology Group (COG) clinical trials
 - Phase 3 trials
 - Pediatric patients diagnosed with high-risk Hodgkin lymphoma
- COG AHOD1331 (2015-2019)
 - 200 labeled cases
 - Internal cohort
- COG AHOD0831 (2009-2012)
 - 97 labeled cases
 - External cohort



Labeled
Baseline PET




Labeled
Interim PET

- Two Children's Oncology Group (COG) clinical trials
 - Phase 3 trials
 - Pediatric patients diagnosed with high-risk Hodgkin lymphoma
- COG AHOD1331 (2015-2019)
 - 200 labeled cases
 - Internal cohort
- COG AHOD0831 (2009-2012)
 - 97 labeled cases
 - External cohort



Labeled
Baseline PET




Labeled
Interim PET

Methods




- Longitudinal-aware segmentation network (LAS-Net)
 - 3D SwinUNETR



Methods




- Longitudinal-aware segmentation network (LAS-Net)
 - 3D SwinUNETR



Methods




- Longitudinal-aware segmentation network (LAS-Net)
 - 3D SwinUNETR
 - Dual-branch with longitudinal cross-attention



Methods




- Longitudinal-aware segmentation network (LAS-Net)
 - 3D SwinUNETR
 - Dual-branch with longitudinal cross-attention
 - One-way information flow




Methods




- Longitudinal-aware segmentation network (LAS-Net)
 - 3D SwinUNETR
 - Dual-branch with longitudinal cross-attention
 - One-way information flow



- Joint optimization for baseline and interim PET segmentation
 - Cross-entropy and Dice loss
 - Patch inputs ($112 \times 112 \times 112$) from co-registered PET scans
- Evaluation metrics
 - Detection **F1 scores** for interim PET



SUVmax: 8.28 g/ml
SUVpeak: 7.12 g/ml



SUVmax: 5.86 g/ml
SUVpeak: 4.75 g/ml



- Joint optimization for baseline and interim PET segmentation
 - Cross-entropy and Dice loss
 - Patch inputs ($112 \times 112 \times 112$) from co-registered PET scans
- Evaluation metrics
 - Detection **F1 scores** for interim PET
 - Interim **PET biomarkers**: SUVmax, Δ SUVmax, qPET
 - Spearman's **ρ** correlations



- Joint optimization for baseline and interim PET segmentation
 - Cross-entropy and Dice loss
 - Patch inputs ($112 \times 112 \times 112$) from co-registered PET scans
- Evaluation metrics
 - Detection **F1 scores** for interim PET
 - Interim **PET biomarkers**: SUVmax, Δ SUVmax, qPET
 - Spearman's ρ correlations
- Model Comparison
 - DynUNet, SegResNet, SwinUNETR
 - **No** longitudinal cross-attention

How about Deformable Registration?



Mask Propagation through Deformable Registration (MPDR)

**Predicted baseline
lesion mask**



Baseline PET

**Predicted Interim
lesion mask**




Interim PET

How about Deformable Registration?




Mask Propagation through Deformable Registration (MPDR)



How about Deformable Registration?




Mask Propagation through Deformable Registration (MPDR)



Results – Detection Performance




- Without MPDR, the detection **F1 score** was **0.61**



Results – Detection Performance




- Without MPDR, the detection **F1 score** was **0.61**
- With MPDR, no increase in the F1 score



Results – Quantitative PET biomarkers



- Agreement with physician measurements
 - **SUVmax**: $\rho=0.79$





Results – Quantitative PET biomarkers



- Agreement with physician measurements
 - **SUVmax**: $\rho=0.79$
 - **Δ SUVmax**: $\rho=0.80$

Without MPDR With MPDR






Results – Quantitative PET biomarkers



- Agreement with physician measurements
 - **SUVmax**: $\rho=0.79$
 - **Δ SUVmax**: $\rho=0.80$
 - **qPET**: $\rho=0.78$

Without MPDR With MPDR






Results – Quantitative PET biomarkers



- Agreement with physician measurements
 - **SUVmax**: $\rho=0.79$
 - **Δ SUVmax**: $\rho=0.80$
 - **qPET**: $\rho=0.78$

Without MPDR With MPDR



Results – Sample Case



— Lymphoma lesions in baseline PET — Predicted lesions by LAS-Net — DS5 lesions in interim PET

— DS4 lesions in interim PET



— DS3 lesions in interim PET

Physician

LAS-Net

Physician

LAS-Net



Results – Sample Case



— Lymphoma lesions in baseline PET — Predicted lesions by LAS-Net — DS5 lesions in interim PET

— DS4 lesions in interim PET


— DS3 lesions in interim PET

Physician

LAS-Net

Physician

LAS-Net



Results – External Validation on AHOD0831



- The detection **F1 score** on interim PET was **0.52**
- Spearman's ρ correlations of interim PET biomarkers
 - **0.70** for $\Delta\text{SUV}_{\text{max}}$
 - **0.69** for qPET

Results – External Validation on AHOD0831



- The detection **F1 score** on interim PET was **0.52**
- Spearman's ρ correlations of interim PET biomarkers
 - **0.70** for $\Delta\text{SUV}_{\text{max}}$
 - **0.69** for qPET
- Potential reasons for the performance drop
 - Generations of PET/CT **scanners**
 - **Annotation** approaches



- Our study introduced a novel method for detecting and segmenting residual lesions on **interim PET** scans
 - multi-institutional clinical trial
 - pediatric Hodgkin lymphoma
 - **Improved detection performance and higher agreements of interim PET biomarkers**
- **Longitudinal awareness** in analyzing multi-time-point imaging datasets

Thank you

xtie@wisc.edu



arXiv



School of Medicine
and Public Health

UNIVERSITY OF WISCONSIN-MADISON